secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001370053-25-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports Phase 2b RA trial success; rosnilimab hits primary endpoint, 69% CDAI LDA at week 14
--------------------------------------------------------------------------------

- Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).
- At week 14, 69% of rosnilimab-treated patients achieved CDAI low disease activity, described as highest ever reported.
- Favorable safety: no malignancies, no MACE, no serious infection elevation vs placebo; discontinuations low at 1-2%.
- Full week 28 data expected Q2 2025; top-line week 12 rosnilimab UC data now anticipated in Q4 2025.
- CEO states results exceed target product profile in ~$20B U.S. RA market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000010/0001370053-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000010/anab-20250212.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer